Bionano Genomics reported a 3% decline in Q4 revenue to $8.0 million and a 7% drop for the full year, totaling $28.5 million, primarily due to supply constraints in consumables rather than weak demand. Despite these challenges, the company exceeded its installation targets for Optical Genome Mapping (OGM) systems, installing nine systems in the fourth quarter and 32 for the year, significantly surpassing the initial guidance of 15 to 20 installations. The focus on routine-use customers, who account for 83% of consumables revenue, is central to Bionano’s strategy moving forward.
The company has made strides in improving profitability, with non-GAAP gross margins rising to 43% for Q4 and 47% for the year, reflecting a significant operational transformation. Bionano’s cash position remains strong, with $29.6 million available and a runway extending into 2027, alongside plans to retire convertible debt by May 2026, simplifying the balance sheet.
A key takeaway for investors is Bionano’s strategic pivot towards enhancing revenue predictability by prioritizing high-volume routine-use customers and focusing on software advancements, which should bolster future growth and profitability as manufacturing constraints ease.
Source: fool.com